Drug Profile
Amlodipine/fimasartan/hydrochlorothiazide - Boryung Pharmaceutical
Alternative Names: BR1010Latest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Amines; Antihypertensives; Benzothiadiazines; Dihydropyridines; Esters; Ischaemic heart disorder therapies; Natriuretic agents; Pyrimidinones; Small molecules; Tetrazoles; Vasodilators
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Hypertension
Most Recent Events
- 22 Apr 2022 Amlodipine/fimasartan/hydrochlorothiazide is still in phase III FINAL trial for Hypertension (Treatment-experienced) in South Korea (NCT03991442)
- 02 Mar 2021 Boryung Pharmaceutical completed the phase III FINAL trial in Hypertension (Treatment-experienced) in South Korea (NCT03991442)
- 01 Oct 2019 Chemical structure information added